Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
1–1
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants will be 1 to less than 2 years of age on day 1 of the relevant part of the study
Homozygous for F508del (F/F)
You may not be if
Any clinically significant laboratory abnormalities at the screening visit that would interfere with the study assessments or pose an undue risk for the participants
Solid organ or hematological transplantation
Clareo Health | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
